This study demonstrates that continuous IFX therapy modified cellular immune activation in the blood from IBD patients, which was characterized by a significant disequilibrium in percentages of CD4+ and CD8+ T-cells, CD38+ T and B cells, and also memory CD4+ cells (CD45RO+). The gene discussed is CD4; the disease is inflammatory bowel disease.